C. trachomatis is the most frequent STD in the United States, with about 3 million cases emerging annually causing from 250,000 to 500,000 cases of pelvic inflammatory disease and 250,000 cases of epididymitis. In addition, the infection facilitates HIV transmission. The disease is generally unrecognized or inadequately treated; infertility, ectopic pregnancy, or chronic pelvic pain may result from the infection ascending the reproductive tract^{1, 3}.

C. trachomatis infection could be transmitted through unprotected vaginal, anal, or oral sex. Infection can be transmitted from infected mother to infant during vaginal childbirth. Moreover, the risk of transmission rises as the number of sexual partners increases^{3, 4}.

Hyris offers an innovative approach of validating and integrating on its platform the best CE-IVD kits from reagent manufacturers on the market.

For the C. trachomatis kit, Hyris provide an innovative test with specific characteristics:

• CE-IVD-marked
• Validated on biological matrices such as: dry swabs and liquid-phase pap smears
• Validated in Real-Time PCR by direct amplification - without DNA or RNA extraction

1. Black M., Current methods of laboratory diagnosis of Chlamydia trachomatis infections, Clin Microbiol Rev, 1997;10(1):160-84
2. Johnson R.E. et al, Screening tests to detect C. trachomatis and Neisseria gonorrhoeae infections, MMWR, Recommendations and Reports, 2022, 51(RR15);1-27
3. Schaeffer A. et al, Rapid detection of C. trachomatis and typing of the lymphogranuloma venereum associated L-Serovars by TacMan PCR, BMC Infectious Diseases, 2008, 8:56
4. Jalal H. et al, C. trachomatis ompA variants in trachoma: what do they tell us?, Plos Negl Trop Dis, 2008; 2(9): e306